FDA Restricts Use of Immunotherapies in Gastric, Esophageal Cancers

(MedPage Today) -- The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction (GEJ), and esophageal cancers, according to letters sent to the respective drugmakers.
The agency had...